Market Forecasts for Immuno-Oncology Diagnostics 2023: Outcome Potential and Companion Diagnostics Driving Growth
Dublin, Jan. 16, 2023 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.
Diagnostics, companion diagnostics, is driving the success of Immuno-oncology Therapeutics. An entire new segment of the diagnostics industry is being created. And its not a small segment either. It promises to grow dramatically. Histology, genomics and liquid biopsy are converging. A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer. The approach seems to be working and showing great promise.
A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.
Technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size in this new expanded and comprehensive report.
Key Topics Covered:
1. Market Guides
2. Introduction and Market Definition
3. Immunotherapy - Guide to Immune Technologies
3.1. The Immune System
3.1.1. Innate immune system
3.1.1.1. Surface barriers
3.1.1.2. Inflammation
3.1.1.3. Complement system
3.1.1.4. Cellular barriers
3.1.1.5. Natural killer cells
3.1.2. Adaptive immune system
3.1.2.1. Lymphocytes
3.1.2.2. Killer T cells
3.1.2.3. Helper T cells
3.1.2.4. Gamma delta T cells
3.1.2.5. B lymphocytes and antibodies
3.1.3. Tumor immunology - the immune surveillance system
3.2. Immuno Oncology Diagnostics
3.2.1. Checkpoint Assays
3.2.1.1. Outlook for Checkpoint Assays
3.2.2. Cytokine Assays
3.2.2.1. Outlook for Cytokine Assays
3.2.3. Genomic Germline
3.2.3.1. Outlook for Genomic Germline
3.2.4. Genomic Tumour
3.2.4.1. Outlook for Genomic Tumour
3.2.5. Tumor Microenviroment
3.2.5.1. Outlook for Tumor Microenvironment
3.2.6. Others
3.2.6.1. Outlook for Other Diagnostics
4. Industry Overview
5. Market Trends
5.1. Factors Driving Growth
5.1.1. Outcome potential
5.1.2. Companion Diagnostics
5.1.3. Funding
5.1.4. Technology Environment
5.1.5. Target Solutions
5.2. Factors Limiting Growth
5.2.1. Complex Role of Diagnostics
5.2.2. Clinical Trials Role
5.2.3. Protocols
5.3. Diagnostic Technology Development
5.3.1. Combinations-Issues and Complexity
5.3.2. Shifting Role of Diagnostics
5.3.3. Multiplexing and Foundation One
5.3.4. The Disruption Dynamic
5.3.5. The Race for Biomarkers
5.3.6. The Next Five Years
6. Cancer Immuno-Oncology Diagnostics Recent Developments
7. Profiles of Key Immuno-oncology Companies
8. The Global Market for Immuno-Oncology Diagnostics
9. Global Immuno-Oncology Diagnostic Markets - By Application
9.1. Checkpoint
9.2. Cytokine
9.3. Germline Genetic
9.4. Genetic Tumor
9.5. Tumor Microenvironment
9.6. Other
10. Global Immuno-Oncology Diagnostic Markets - By Technology
10.1. NGS
10.2. PCR
10.3. Fish/IHC
10.4. Chem/IA
10.5. Other Technology
11. Global Immuno-Oncology Diagnostic Markets - By Customer
12. Appendices
Companies Mentioned
10x Genomics, Inc.
Abbott Laboratories
AccuraGen Inc.
Aethlon Medical
Agilent/Dako
Anchor Dx
ANGLE plc
AVIVA Systems Biology
Baylor Miraca Genetics Laboratories
Becton, Dickinson and Company
Berkley Lights
BGI Genomics Co. Ltd
Bioarray Genetics
Biocartis
Biocept, Inc.
Biodesix Inc.
BioFluidica
BioGenex
BioIVT
Biolidics Ltd
bioMerieux Diagnostics
Bioneer Corporation
Bio-Rad Laboratories, Inc.
Bio-Reference Laboratories
Bio-Techne
Bioview
Bolidics
Boreal Genomics
Bristol-Myers Squibb
Burning Rock
Cardiff Oncology
Caris Molecular Diagnostics
Castle Biosciences, Inc.
CellCarta
CellMax Life
Cepheid (Danaher)
Charles River Laboratories
Circulogene
Cizzle Biotech
Clinical Genomics
Cytolumina Technologies Corp.
Datar Cancer Genetics Limited
Diagnologix LLC
Diasorin S.p.A.
Dxcover
Element Biosciences
Enzo Biochem
Epic Sciences
Epigenomics AG
Eurofins Scientific
Fabric Genomics
Fluxion Biosciences
Freenome
FUJIFILM Wako Diagnostics
Fyr Diagnostics
GeneFirst Ltd.
Genetron Holdings
GenomOncology
GILUPI Nanomedizin
Guardant Health
HansaBiomed
HeiScreen
Helomics
HTG Molecular Diagnostics
iCellate
ICON PLC
Illumina
Incell Dx
Inivata
INOVIQ
Integrated Diagnostics
Invitae Corporation
Invivogen
Invivoscribe
Janssen Diagnostics
Lunglife AI Inc
MDNA Life SCIENCES, Inc.
MDx Health
Menarini Silicon Biosystems
Mesa Laboratories, Inc.
Millipore Sigma
Miltenyi Biotec
miR Scientific
Myriad Genetics/Myriad RBM
NantHealth, Inc.
Natera
NeoGenomics
NGeneBio
Novogene Bioinformatics Technology Co., Ltd.
Oncocyte
OncoDNA
Ortho Clinical Diagnostics
Oxford Nanopore Technologies
PamGene
Panagene
Perkin Elmer
Personal Genome Diagnostics
Personalis
Precipio
Precision Medicine Group
PrecisionMed
Predicine
Promega
Qiagen
Rarecells SAS
RareCyte
Roche Molecular Diagnostics
Screencell
Sense Biodetection
Siemens Healthineers
simfo GmbH
Singlera Genomics Inc.
Singular Genomics
Singulomics
SkylineDx
Standard BioTools
Stilla Technologies
Sysmex Inostics
Tempus Labs, Inc.
Thermo Fisher Scientific Inc.
Todos Medical
Ultima Genomics
Veracyte
Volition
Vortex Biosciences
For more information about this report visit https://www.researchandmarkets.com/r/rvc54j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
